Thyroid Toxicogenomics: A Multi-Organ Paradigm

Toxicogenomics-Based Cellular Models: Alternatives to Animal Testing for Safety Assessment

Volumn , Issue , 2014, Pages 159-189

  Jomaa, Barae ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

Endocrine disruption; HPT axis; Thyroid hormones; Toxicogenomics

Indexed keywords

EID: 84903402205     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978012397862200009-7     Document Type: Chapter

References (190)

1. Terris D, Gourin C Thyroid and parathyroid diseases: medical and surgical management 2008, Thieme.
2. Temple RKG, Needham J The genius of China: 3,000 years of science, discovery, and invention 2007, Inner Traditions, Rochester, VT.
3. Encyclopedia Britannica Online. Paracelsus,<>; 2013. http://www.britannica.com/EBchecked/topic/442424/Paracelsus.
4. Kelly FC Iodine in medicine and pharmacy since its discovery: 1811-1961. Proc R Soc Med 1961, 54:831-836.
5. Kendall EC The isolation in crystalline form of the compound containing iodin, which occurs in the thyroid. JAMA 1915, 64:2042-2043.
6. Gross J, Pitt-Rivers R The identification of 3:5:3'-L-triiodothyronine in human plasma. Lancet 1952, 1:439-441.
7. Lieberman AJ. Facts versus fears: a review of the greatest unfounded health scares of recent times. American Council on Science and Health; 2004.
8. Axelson O, Sundell L, Andersson K, Edling C, Hogstedt C, Kling H Herbicide exposure and tumor mortality: an updated epidemiologic investigation on Swedish railroad workers. Scand J Work Environ Health 1980, 6:73-79.
9. Alison RH, Capen CC, Prentice DE Neoplastic lesions of questionable significance to humans. Toxicol Pathol 1994, 22:179-186.
10. USEPA RED facts amitrole 1996, US Environmental Protection Agency, Office of Prevention, Pesticides and Toxic Substances, Washington DC.
11. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR, Lee D-H, et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev 2012, 33:378-455.
12. Palmblad J, Levi L, Burger A, Melander A, Westgren U, von Schenck H, et al. Effects of total energy withdrawal (fasting) on the levels of growth hormone, thyrotropin, cortisol, adrenaline, noradrenaline, T4, T3, and rT3 in healthy males. Acta Med Scand 1977, 201:15-22.
13. Hackney AC, Feith S, Pozos R, Seale J Effects of high altitude and cold exposure on resting thyroid hormone concentrations. Aviat Space Environ Med 1995, 66:325-329.
14. Singh DV, Turner CW Effect of light and darkness upon thyroid secretion rate and on the endocrine glands of female rats. Proc Soc Exp Biol Med 1969, 131:1296-1299.
15. Roth GS, Handy AM, Mattison JA, Tilmont EM, Ingram DK, Lane MA Effects of dietary caloric restriction and aging on thyroid hormones of rhesus monkeys. Horm Metab Res 2002, 34:378-382.
16. Tingley JO, Morris AW, Hill SR, Pittman JA The acute thyroid response to emotional stress. Ala J Med Sci 1965, 2:297-300.
17. Chan V, Wang C, Yeung RT Pituitary-thyroid responses to surgical stress. Acta Endocrinol 1978, 88:490-498.
18. Capen CC, Martin SL The effects of xenobiotics on the structure and function of thyroid follicular and C-cells. Toxicol Pathol 1989, 17:266-293.
19. Franklyn JA, Ramsden DB, Sheppard MC The influence of age and sex on tests of thyroid function. Ann Clin Biochem 1985, 22(5):502-505.
20. Andersen S, Pedersen KM, Bruun NH, Laurberg P Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab 2002, 87:1068-1072.
21. Hansen PS, Brix TH, Sørensen TIA, Kyvik KO, Hegedüs L Major genetic influence on the regulation of the pituitary-thyroid axis: a study of healthy Danish twins. J Clin Endocrinol Metab 2004, 89:1181-1187.
22. Shirai T, Asamoto M Application of toxicogenomics to the endocrine disruption issue. Pure Appl Chem 2003, 75:2419-2422.
23. Werthmann RC, Volpe S, Lohse MJ, Calebiro D Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells. FASEB J 2012, 26:2043-2048.
24. Wonerow P, Chey S, Führer D, Holzapfel HP, Paschke R Functional characterization of five constitutively activating thyrotrophin receptor mutations. Clin Endocrinol 2000, 53:461-468.
25. Hochbaum D, Hong K, Barila G, Ribeiro-Neto F, Altschuler DL Epac, in synergy with cAMP-dependent protein kinase (PKA), is required for cAMP-mediated mitogenesis. J Biol Chem 2008, 283:4464-4468.
26. Minich WB, Lenzner C, Bergmann A, Morgenthaler NG A coated tube assay for the detection of blocking thyrotropin receptor autoantibodies. J Clin Endocrinol Metab 2004, 89:352-356.
27. Titus S, Neumann S, Zheng W, Southall N, Michael S, Klumpp C, et al. Quantitative high throughput screening using a live cell cAMP assay identifies small molecule agonists of the TSH receptor. J Biomol Screen 2008, 13:120-127.
28. Evans C, Morgenthaler NG, Lee S, Llewellyn DH, Clifton-Bligh R, John R, et al. Development of a luminescent bioassay for thyroid stimulating antibodies. J Clin Endocrinol Metab 1999, 84:374-377.
29. Jomaa B, Aarts JMMJG, de Haan LHJ, Peijnenburg AACM, Bovee TFH, Murk AJ, et al. In vitro pituitary and thyroid cell proliferation assays and their relevance as alternatives to animal testing. ALTEX 2013, 30:293-307.
30. Maruo Y, Takahashi H, Soeda I, Nishikura N, Matsui K, Ota Y, et al. Transient congenital hypothyroidism caused by biallelic mutations of the dual oxidase 2 gene in Japanese patients detected by a neonatal screening program, J. Clin Endocrinol Metab 2008, 93:4261-4267.
31. Zamproni I, Grasberger H, Cortinovis F, Vigone MC, Chiumello G, Mora S, et al. Biallelic inactivation of the dual oxidase maturation factor 2 (DUOXA2) gene as a novel cause of congenital hypothyroidism. J Clin Endocrinol Metab 2008, 93:605-610.
32. Rigutto S, Hoste C, Grasberger H, Milenkovic M, Communi D, Dumont JE, et al. Activation of dual oxidases Duox1 and Duox2 differential regulation mediated by cAMP-dependent protein kinase and protein kinase C-dependent phosphorylation. J Biol Chem 2009, 284:6725-6734.
33. Milenkovic M, De Deken X, Jin L, De Felice M, Di Lauro R, Dumont JE, et al. Duox expression and related H2O2 measurement in mouse thyroid: onset in embryonic development and regulation by TSH in adult. J Endocrinol 2007, 192:615-626.
34. Fernandez N, Caloca MJ, Prendergast GV, Meinkoth JL, Kazanietz MG Atypical protein kinase C-zeta stimulates thyrotropin-independent proliferation in rat thyroid cells. Endocrinology 2000, 141:146-152.
35. Akama T, Hara T, Yan D, Kawashima A, Yoshihara A, Sue M, et al. Thyroglobulin induces thyroid cell growth through suppression of miR-16 and miR-195, 2012.
36. Heijne WHM, Kienhuis AS, van Ommen B, Stierum RH, Groten JP Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology. Expert Rev Proteomics 2005, 2:767-780.
37. Hays MT Compartmental models for human iodine metabolism. Math Biosci 1984, 72:317-335.
38. Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, et al. Na+/I-symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 1998, 83:4102-4106.
39. Eskandari S, Loo DDF, Dai G, Levy O, Wright EM, Carrasco N Thyroid Na+/I-symporter mechanism, stoichiometry, and specificity. J Biol Chem 1997, 272:27230-27238.
40. Dohán O, la Vieja AD, Paroder V, Riedel C, Artani M, Reed M, et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 2003, 24:48-77.
41. Josefsson M, Evilevitch L, Weström B, Grunditz T, Ekblad E Sodium-iodide symporter mediates iodide secretion in rat gastric mucosa in vitro. Exp Biol Med (Maywood) 2006, 231:277-281.
42. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 2004, 101:6062-6067.
43. Everett LA, Glaser B, Beck JC, Idol JR, Buchs A, Heyman M, et al. Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet 1997, 17:411-422.
44. Pesce L, Bizhanova A, Caraballo JC, Westphal W, Butti ML, Comellas A, et al. TSH regulates pendrin membrane abundance and enhances iodide efflux in thyroid cells. Endocrinology 2012, 153:512-521.
45. Twyffels L, Massart C, Golstein PE, Raspe E, van Sande J, Dumont JE, et al. Pendrin: the thyrocyte apical membrane iodide transporter?. Cell Physiol Biochem 2011, 28:491-496.
46. Cohn WE, Cohn ET Permeability of red corpuscles of the dog to sodium ion. Proc Soc Exp Biol Med 1939, 41:445-449.
47. Huxley A From overshoot to voltage clamp. Trends Neurosci 2002, 25:553-558.
48. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981, 391:85-100.
49. Di Bernardo J, Iosco C, Rhoden KJ Intracellular anion fluorescence assay for sodium/iodide symporter substrates. Anal Biochem 2011, 415:32-38.
50. Yoshida A, Taniguchi S, Hisatome I, Royaux IE, Green ED, Kohn LD, et al. Pendrin is an iodide-specific apical porter responsible for iodide efflux from thyroid cells. J Clin Endocrinol Metab 2002, 87:3356-3361.
51. Gillam MP, Sidhaye AR, Lee EJ, Rutishauser J, Stephan CW, Kopp P Functional characterization of pendrin in a polarized cell system: evidence for pendrin-mediated apical iodide efflux. J Biol Chem 2004, 279:13004-13010.
52. Suzuki K, Kohn LD Differential regulation of apical and basal iodide transporters in the thyroid by thyroglobulin. J Endocrinol 2006, 189:247-255.
53. Schweizer U, Chiu J, Köhrle J Peroxides and peroxide-degrading enzymes in the thyroid. Antioxid Redox Signal 2008, 10:1577-1592.
54. Bou Khalil R, Richa S Thyroid adverse effects of psychotropic drugs: a review. Clin Neuropharmacol 2011, 34:248-255.
55. Schmutzler C, Bacinski A, Gotthardt I, Huhne K, Ambrugger P, Klammer H, et al. The ultraviolet filter benzophenone 2 interferes with the thyroid hormone axis in rats and is a potent in vitro inhibitor of human recombinant thyroid peroxidase. Endocrinology 2007, 148:2835-2844.
56. de Souza Dos Santos MC, Gonçalves CFL, Vaisman M, Ferreira ACF, de Carvalho DP Impact of flavonoids on thyroid function. Food Chem Toxicol 2011, 49:2495-2502.
57. Senou M, Khalifa C, Thimmesch M, Jouret F, Devuyst O, Col V, et al. A coherent organization of differentiation proteins is required to maintain an appropriate thyroid function in the pendred thyroid. J Clin Endocrinol Metab 2010, 95:4021-4030.
58. Ekholm R, Björkman U Glutathione peroxidase degrades intracellular hydrogen peroxide and thereby inhibits intracellular protein iodination in thyroid epithelium. Endocrinology 1997, 138:2871-2878.
59. Masini-Repiso AM, Bonaterra M, Spitale L, Di Fulvio M, Bonino MI, Coleoni AH, et al. Ultrastructural localization of thyroid peroxidase, hydrogen peroxide-generating sites, and monoamine oxidase in benign and malignant thyroid diseases. Hum Pathol 2004, 35:436-446.
60. Antonica F, Kasprzyk DF, Opitz R, Iacovino M, Liao X-H, Dumitrescu AM, et al. Generation of functional thyroid from embryonic stem cells. Nature 2012, 491:66-71.
61. Yoshihara A, Hara T, Kawashima A, Akama T, Tanigawa K, Wu H, et al. Regulation of dual oxidase (DUOX) expression and H2O2 production by thyroglobulin. Thyroid 2012, 10.1089/thy.2012-0003.
62. Sugawara M, Sugawara Y, Wen K Methimazole and propylthiouracil increase cellular thyroid peroxidase activity and thyroid peroxidase mRNA in cultured porcine thyroid follicles. Thyroid 1999, 9:513-518.
63. Song M, Kim Y-J, Song M-K, Choi H-S, Park Y-K, Ryu J-C Identification of classifiers for increase or decrease of thyroid peroxidase activity in the FTC-238/hTPO recombinant cell line. Environ Sci Technol 2011, 45:7906-7914.
64. Hirakawa S, Saito R, Ohara H, Okuyama R, Aiba S Dual oxidase 1 induced by Th2 cytokines promotes STAT6 phosphorylation via oxidative inactivation of protein tyrosine phosphatase 1B in human epidermal keratinocytes. J Immunol 2011, 186:4762-4770.
65. Selmi S, Rousset B Identification of two subpopulations of thyroid lysosomes: relation to the thyroglobulin proteolytic pathway. Biochem J 1988, 253:523-532.
66. Radvila A, Roost R, Bürgi H, Kohler H, Studer H Inhibition of thyroglobulin biosynthesis and degradation by excess iodide: synergism with lithium. Acta Endocrinol 1976, 81:495-506.
67. Jegga AG, Schneider L, Ouyang X, Zhang J Systems biology of the autophagy-lysosomal pathway. Autophagy 2011, 7:477-489.
68. Dennemärker J, Lohmüller T, Müller S, Aguilar SV, Tobin DJ, Peters C, et al. Impaired turnover of autophagolysosomes in cathepsin L deficiency. Biol Chem 2010, 391:913-922.
69. Wille A, Gerber A, Heimburg A, Reisenauer A, Peters C, Saftig P, et al. Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells. Biol Chem 2004, 385:665-670.
70. Friedrichs B, Tepel C, Reinheckel T, Deussing J, von Figura K, Herzog V, et al. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest 2003, 111:1733-1745.
71. Moreno JC, Keijser R, Aarraas S, De Vijlder JJM, Ris-Stalpers C Cloning and characterization of a novel thyroidal gene encoding proteins with a conserved nitroreductase domain. J Endocrinol Invest 2002, 25:40.
72. Afink G, Kulik W, Overmars H, de Randamie J, Veenboer T, van Cruchten A, et al. Molecular characterization of iodotyrosine dehalogenase deficiency in patients with hypothyroidism. J Clin Endocrinol Metab 2008, 93:4894-4901.
73. Moreno JC, Klootwijk W, van Toor H, Pinto G, D'Alessandro M, Lèger A, et al. Mutations in the iodotyrosine deiodinase gene and hypothyroidism. N Engl J Med 2008, 358:1811-1818.
74. Thomas SR, McTamney PM, Adler JM, LaRonde-LeBlanc N, Rokita SE Crystal structure of iodotyrosine deiodinase, a novel flavoprotein responsible for iodide salvage in thyroid glands. J Biol Chem 2009, 284:19659-19667.
75. Gnidehou S, Caillou B, Talbot M, Ohayon R, Kaniewski J, Noël-Hudson M-S, et al. Iodotyrosine dehalogenase 1 (DEHAL1) is a transmembrane protein involved in the recycling of iodide close to the thyroglobulin iodination site. FASEB J 2004, 18:1574-1576.
76. Marangell LB, George MS, Callahan AM, Ketter TA, Pazzaglia PJ, L'Herrou TA, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 1997, 54:214-222.
77. Schmitmeier S, Thole H, Bader A, Bauer K Purification and characterization of the thyrotropin-releasing hormone (TRH)-degrading serum enzyme and its identification as a product of liver origin. Eur J Biochem 2002, 269:1278-1286.
78. Jones BW, Hinkle PM Subcellular trafficking of the TRH receptor: effect of phosphorylation. Mol Endocrinol 2009, 23:1466-1478.
79. Joffe RT, Gold PW, Uhde TW, Post RM The effects of carbamazepine on the thyrotropin response to thyrotropin-releasing hormone. Psychiatry Res 1984, 12:161-166.
80. Rosen JB, Weiss SR, Post RM Contingent tolerance to carbamazepine: alterations in TRH mRNA and TRH receptor binding in limbic structures. Brain Res 1994, 651:252-260.
81. Sun Y, Lu X, Gershengorn MC Thyrotropin-releasing hormone receptors: similarities and differences. J Mol Endocrinol 2003, 30:87-97.
82. Engel S, Neumann S, Kaur N, Monga V, Jain R, Northup J, et al. Low affinity analogs of thyrotropin-releasing hormone are super-agonists. J Biol Chem 2006, 281:13103-13109.
83. O'Dowd BF, Lee DK, Huang W, Nguyen T, Cheng R, Liu Y, et al. TRH-R2 exhibits similar binding and acute signaling but distinct regulation and anatomic distribution compared with TRH-R1. Mol Endocrinol 2000, 14:183-193.
84. Wang W, Gershengorn MC Rat TRH receptor type 2 exhibits higher basal signaling activity than TRH receptor type 1. Endocrinology 1999, 140:4916-4919.
85. Mittal SR, Mathur AK, Prasad N Effect of calcium channel blockers on serum levels of thyroid hormones. Int J Cardiol 1993, 38:131-132.
86. Teba L, Smailer S, Taylor HC Effect of nifedipine on TRH stimulation of TSH and PRL release by the pituitary gland. Metab Clin Exp 1985, 34:161-163.
87. Yamada M, Mori M, Yamaguchi M, Akiyama H, Shiono S, Kobayashi I, et al. Thyrotropin-releasing hormone stimulation of thyrotropin secretion is suppressed by calcium ion antagonists that block transmembrane influx and intracellular mobilization of calcium ion in human subjects. J Endocrinol Invest 1986, 9:227-231.
88. Segev DL, Umbricht C, Zeiger MA Molecular pathogenesis of thyroid cancer. Surg Oncol 2003, 12:69-90.
89. Ahmed E-L, Steve O Pituitary thyroid hormone resistance (PTHR). Endocr Abstr 2011, 25:P66.
90. Ravindra R, Forman LJ, Patel SA Vinblastine and nocodazole inhibit basal and thyrotropin-releasing hormone-stimulated prolactin secretion in GH(3) cells. Endocrine 1995, 3:591-596.
91. Liu C, Ha M, Cui Y, Wang C, Yan M, Fu W, et al. JNK pathway decreases thyroid hormones via TRH receptor: a novel mechanism for disturbance of thyroid hormone homeostasis by PCB153. Toxicology 2012, 302:68-76.
92. Millipore, Millipore TRH receptor assay, 2012.
93. PerklinElmer, AequoScreen® GPCR Cell Line, 2009.
94. Shimomura O, Johnson FH, Saiga Y Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. J Cell Comp Physiol 1962, 59:223-239.
95. Martin A, Platzer M, Davies TF Retention of cyclic AMP response to TSH in a cloned human thyrocyte/T cell hybridoma (HY2-15). Mol Cell Endocrinol 1988, 60:233-238.
96. James RA, Sarapura VD, Bruns C, Raulf F, Dowding JM, Gordon DF, et al. Thyroid hormone-induced expression of specific somatostatin receptor subtypes correlates with involution of the TtT-97 murine thyrotrope tumor. Endocrinology 1997, 138:719-724.
97. Alarid ET, Windle JJ, Whyte DB, Mellon PL Immortalization of pituitary cells at discrete stages of development by directed oncogenesis in transgenic mice. Development 1996, 122:3319-3329.
98. Aizawa S, Sakai T, Sakata I Glutamine and glutamic acid enhance thyroid-stimulating hormone β subunit mRNA expression in the rat pars tuberalis. J Endocrinol 2012, 212:383-394.
99. Gavras I, Thomson JA Late thyrotoxicosis complicating autoimmune thyroiditis. Acta Endocrinol 1972, 69:41-46.
100. Shibusawa N, Hashimoto K, Yamada M Thyrotropin-releasing hormone (TRH) in the cerebellum. Cerebellum 2008, 7:84-95.
101. Veronesi MC, Yard M, Jackson J, Lahiri DK, Kubek MJ An analog of thyrotropin-releasing hormone (TRH) is neuroprotective against glutamate-induced toxicity in fetal rat hippocampal neurons in vitro. Brain Res 2007, 1128:79-85.
102. Coppola A, Meli R, Diano S Inverse shift in circulating corticosterone and leptin levels elevates hypothalamic deiodinase type 2 in fasted rats. Endocrinology 2005, 146:2827-2833.
103. Nillni EA Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by neuronal and peripheral inputs. Front Neuroendocrinol 2010, 31:134-156.
104. Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, et al. Expression of thyrotropin-releasing hormone by human melanoma and nevi. Clin Cancer Res 2004, 10:5531-5536.
105. Gkonos PJ, Tavianini MA, Liu CC, Roos BA Thyrotropin-releasing hormone gene expression in normal thyroid parafollicular cells. Mol Endocrinol 1989, 3:2101-2109.
106. García SI, Porto PI, Martinez VN, Alvarez AL, Finkielman S, Pirola CJ Expression of TRH and TRH-like peptides in a human glioblastoma-astrocytoma cell line (U-373-MG). J Endocrinol 2000, 166:697-703.
107. Garcia SI, Dabsys SM, Santajuliana D, Delorenzi A, Finkielman S, Nahmod VE, et al. Interaction between thyrotrophin-releasing hormone and the muscarinic cholinergic system in rat brain. J Endocrinol 1992, 134:215-219.
108. Tabunoki H, Saito N, Suwanborirux K, Charupant K, Satoh J Molecular network profiling of U373MG human glioblastoma cells following induction of apoptosis by novel marine-derived anti-cancer 1,2,3,4-tetrahydroisoquinoline alkaloids. Cancer Cell Int 2012, 12:14.
109. Zandieh Doulabi B, Platvoet-ter Schiphorst M, van Beeren HC, Labruyere WT, Lamers WH, Fliers E, et al. TR(beta)1 protein is preferentially expressed in the pericentral zone of rat liver and exhibits marked diurnal variation. Endocrinology 2002, 143:979-984.
110. Abel ED, Ahima RS, Boers ME, Elmquist JK, Wondisford FE Critical role for thyroid hormone receptor beta2 in the regulation of paraventricular thyrotropin-releasing hormone neurons. J Clin Invest 2001, 107:1017-1023.
111. Katz D, Reginato MJ, Lazar MA Functional regulation of thyroid hormone receptor variant TR alpha 2 by phosphorylation. Mol Cell Biol 1995, 15:2341-2348.
112. Yen PM Physiological and molecular basis of thyroid hormone action. Physiol Rev 2001, 81:1097-1142.
113. Carr FE, Wong NC Characteristics of a negative thyroid hormone response element. J Biol Chem 1994, 269:4175-4179.
114. Weiss RE, Xu J, Ning G, Pohlenz J, O'Malley BW, Refetoff S Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone. EMBO J 1999, 18:1900-1904.
115. Freitas J, Cano P, Craig-Veit C, Goodson ML, Furlow JD, Murk AJ Detection of thyroid hormone receptor disruptors by a novel stable in vitro reporter gene assay. Toxicol In Vitro 2011, 25:257-266.
116. Gutleb AC, Meerts IATM, Bergsma JH, Schriks M, Murk AJ T-Screen as a tool to identify thyroid hormone receptor active compounds. Environ Toxicol Pharmacol 2005, 19:231-238.
117. Paquette MA, Dong H, Gagné R, Williams A, Malowany M, Wade MG, et al. Thyroid hormone-regulated gene expression in juvenile mouse liver: identification of thyroid response elements using microarray profiling and in silico analyses. BMC Genomics 2011, 12:634.
118. Feng X, Jiang Y, Meltzer P, Yen PM Thyroid hormone regulation of hepatic genes in vivo detected by complementary DNA microarray. Mol Endocrinol 2000, 14:947-955.
119. Song M, Kim YJ, Lee J-N, Ryu JC Genome-wide expression profiling of carbaryl and vinclozolin in human thyroid follicular carcinoma (FTC-238) cells. BioChip J 2010, 4:89-98.
120. Safi R, Muramoto GG, Salter AB, Meadows S, Himburg H, Russell L, et al. Pharmacological manipulation of the RAR/RXR signaling pathway maintains the repopulating capacity of hematopoietic stem cells in culture. Mol Endocrinol 2009, 23:188-201.
121. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 1995, 377:397-404.
122. Chen JD, Evans RM A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 1995, 377:454-457.
123. Moore JMR, Galicia SJ, McReynolds AC, Nguyen N-H, Scanlan TS, Guy RK Quantitative proteomics of the thyroid hormone receptor-coregulator interactions. J Biol Chem 2004, 279:27584-27590.
124. Johnson RL, Hwang JY, Arnold LA, Huang R, Wichterman J, Augustinaite I, et al. A quantitative high throughput screen identifies novel inhibitors of the interaction of thyroid receptor beta with a peptide of steroid receptor coactivator 2. J Biomol Screen 2011, 16:618-627.
125. Sadana P, Hwang JY, Attia RR, Arnold LA, Neale G, Guy RK Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol 2011, 6:1096-1106.
126. Schussler GC The thyroxine-binding proteins. Thyroid 2000, 10:141-149.
127. Savu L, Vranckx R, Marielle R-R, Maya M, Nunez EA, Tréton J, et al. A senescence up-regulated protein: the rat thyroxine-binding globulin (TBG). Biochim Biophys Acta 1991, 1097:19-22.
128. Sousa JC, de Escobar GM, Oliveira P, Saraiva MJ, Palha JA Transthyretin is not necessary for thyroid hormone metabolism in conditions of increased hormone demand. J Endocrinol 2005, 187:257-266.
129. Carvalho GA, Weiss RE, Refetoff S Complete thyroxine-binding globulin (TBG) deficiency produced by a mutation in acceptor splice site causing frameshift and early termination of translation (TBG-Kankakee). J Clin Endocrinol Metab 1998, 83:3604-3608.
130. Afandi B, Vera R, Schussler GC, Yap MG Concordant decreases of thyroxine and thyroxine binding protein concentrations during sepsis. Metabolism 2000, 49:753-754.
131. Montaño M, Cocco E, Guignard C, Marsh G, Hoffmann L, Bergman A, et al. New approaches to assess the transthyretin binding capacity of bioactivated thyroid hormone disruptors. Toxicol Sci 2012, 130:94-105.
132. Bartalena L, Farsetti A, Flink IL, Robbins J Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells. Mol Endocrinol 1992, 6:935-942.
133. Friesema ECH, Jansen J, Jachtenberg J-W, Visser WE, Kester MHA, Visser TJ Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol 2008, 22:1357-1369.
134. Friesema ECH, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003, 278:40128-40135.
135. Pizzagalli F, Hagenbuch B, Stieger B, Klenk U, Folkers G, Meier PJ Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. Mol Endocrinol 2002, 16:2283-2296.
136. Nishimura M, Naito S Tissue-specific mRNA expression profiles of human solute carrier transporter superfamilies. Drug Metab Pharmacokinet 2008, 23:22-44.
137. van der Deure WM, Peeters RP, Visser TJ Molecular aspects of thyroid hormone transporters, including MCT8, MCT10, and OATPs, and the effects of genetic variation in these transporters. J Mol Endocrinol 2010, 44:1-11.
138. Mayerl S, Visser TJ, Darras VM, Horn S, Heuer H Impact of Oatp1c1 deficiency on thyroid hormone metabolism and action in the mouse brain. Endocrinology 2012, 153:1528-1537.
139. Verhoeven FA, Moerings EP, Lamers JM, Hennemann G, Visser TJ, Everts ME Inhibitory effects of calcium channel blockers on thyroid hormone uptake in neonatal rat cardiomyocytes. Am J Physiol 2001, 281:H1985-H1991.
140. Segal J Calcium is the first messenger for the action of thyroid hormone at the level of the plasma membrane: first evidence for an acute effect of thyroid hormone on calcium uptake in the heart. Endocrinology 1990, 126:2693-2702.
141. Kinne A, Roth S, Biebermann H, Köhrle J, Grüters A, Schweizer U Surface translocation and tri-iodothyronine uptake of mutant MCT8 proteins are cell type-dependent. J Mol Endocrinol 2009, 43:263-271.
142. Westholm DE, Salo DR, Viken KJ, Rumbley JN, Anderson GW The blood-brain barrier thyroxine transporter organic anion-transporting polypeptide 1c1 displays atypical transport kinetics. Endocrinology 2009, 150:5153-5162.
143. Kogai T, Liu Y-Y, Richter LL, Mody K, Kagechika H, Brent GA Retinoic acid induces expression of the thyroid hormone transporter, monocarboxylate transporter 8 (Mct8). J Biol Chem 2010, 285:27279-27288.
144. Capelo LP, Beber EH, Fonseca TL, Gouveia CHA The monocarboxylate transporter 8 and L-type amino acid transporters 1 and 2 are expressed in mouse skeletons and in osteoblastic MC3T3-E1 cells. Thyroid 2009, 19:171-180.
145. Mebis L, Paletta D, Debaveye Y, Ellger B, Langouche L, D'Hoore A, et al. Expression of thyroid hormone transporters during critical illness. Eur J Endocrinol 2009, 161:243-250.
146. Sugiyama D, Kusuhara H, Taniguchi H, Ishikawa S, Nozaki Y, Aburatani H, et al. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. J Biol Chem 2003, 278:43489-43495.
147. Benedetti MS, Whomsley R, Baltes E, Tonner F Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. Eur J Clin Pharmacol 2005, 61:863-872.
148. Huang SA, Bianco AC Reawakened interest in type III iodothyronine deiodinase in critical illness and injury. Nat Clin Pract Endocrinol Metab 2008, 4:148-155.
149. Wu S-Y, Green WL, Huang W-S, Hays MT, Chopra IJ Alternate pathways of thyroid hormone metabolism. Thyroid 2005, 15:943-958.
150. Xu C, Li CY-T, Kong A-NT Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005, 28:249-268.
151. Visser TJ, Kaptein E, Gijzel AL, de Herder WW, Ebner T, Burchell B Glucuronidation of thyroid hormone by human bilirubin and phenol UDP-glucuronyltransferase isoenzymes. FEBS Lett 1993, 324:358-360.
152. Findlay KA, Kaptein E, Visser TJ, Burchell B Characterization of the uridine diphosphate-glucuronosyltransferase-catalyzing thyroid hormone glucuronidation in man. J Clin Endocrinol Metab 2000, 85:2879-2883.
153. Wieneke N, Neuschäfer-Rube F, Bode LM, Kuna M, Andres J, Carnevali LC, et al. Synergistic acceleration of thyroid hormone degradation by phenobarbital and the PPAR alpha agonist WY14643 in rat hepatocytes. Toxicol Appl Pharmacol 2009, 240:99-107.
154. Zavacki AM, Larsen PR CARs and drugs: a risky combination. Endocrinology 2005, 146:992-994.
155. Everts ME, Visser TJ, Moerings EP, Docter R, van Toor H, Tempelaars AM, et al. Uptake of triiodothyroacetic acid and its effect on thyrotropin secretion in cultured anterior pituitary cells. Endocrinology 1994, 135:2700-2707.
156. Juge-Aubry CE, Morin O, Pernin AT, Liang H, Philippe J, Burger AG Long-lasting effects of Triac and thyroxine on the control of thyrotropin and hepatic deiodinase type I. Eur J Endocrinol 1995, 132:751-758.
157. Lameloise N, Siegrist-Kaiser C, O'Connell M, Burger A Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy. Eur J Endocrinol 2001, 144:145-154.
158. Gavin LA, Livermore BM, Cavalieri RR, Hammond ME, Castle JN Serum concentration, metabolic clearance, and production rates of 3,5,3'triiodothyroacetic acid in normal and athyreotic man. J Clin Endocrinol Metab 1980, 51:529-534.
159. FDA, FDA and the U.S. Attorney for the Western District of Texas Announce Guilty Plea in Drug Counterfeiting Case, 2004 Press release accessed on . http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108266.htm.
160. FDA, Tiratricol (triiodothyroacetic acid). Safety Alerts for Human Medical Products 2009.
161. Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, et al. 3-iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 2004, 10:638-642.
162. Murk AJ, Rijntjes E, Blaauboer BJ, Clewell R, Crofton KM, Dingemans MML, et al. Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol In Vitro 2013, 10.1016/j.tiv.2013.02.012.
163. Shah RB, Bryant A, Collier J, Habib MJ, Khan MA Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients. Int J Pharm 2008, 360:77-82.
164. Režen T, Juvan P, Tacer KF, Kuzman D, Roth A, Pompon D, et al. The Sterolgene v0 cDNA microarray: a systemic approach to studies of cholesterol homeostasis and drug metabolism. BMC Genomics 2008, 9:76.
165. Gruters A Molecular genetic defects in congenital hypothyroidism. Eur J Endocrinol 2004, 151:U39-U44.
166. Kuehnen P, Grueters A, Krude H Two puzzling cases of thyroid dysgenesis. Horm Res 2009, 71:93-97.
167. Castanet M, Sura-Trueba S, Chauty A, Carré A, de Roux N, Heath S, et al. Linkage and mutational analysis of familial thyroid dysgenesis demonstrate genetic heterogeneity implicating novel genes. Eur J Hum Genet 2005, 13:232-239.
168. Felice MD, Lauro RD Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev 2004, 25:722-746.
169. Vassart G, Dumont JE Thyroid dysgenesis: multigenic or epigenetic .. or both?. Endocrinology 2005, 146:5035-5037.
170. Atkins P, Cohen SB, Phillips BJ Drug therapy for hyperthyroidism in pregnancy: safety issues for mother and fetus. Drug Saf 2000, 23:229-244.
171. Gorman CA Radioiodine and pregnancy. Thyroid 1999, 9:721-726.
172. Olivieri A, Stazi MA, Mastroiacovo P, Fazzini C, Medda E, Spagnolo A, et al. A population-based study on the frequency of additional congenital malformations in infants with congenital hypothyroidism: data from the Italian Registry for Congenital Hypothyroidism (1991-1998). J Clin Endocrinol Metab 2002, 87:557-562.
173. Panicker V Genetics of thyroid function and disease. Clin Biochem Rev 2011, 32:165-175.
174. Brix TH, Kyvik KO, Christensen K, Hegedüs L Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001, 86:930-934.
175. McLeod DSA, Cooper DS The incidence and prevalence of thyroid autoimmunity. Endocrine 2012, 42:252-265.
176. Rose NR, Rasooly L, Saboori AM, Burek CL Linking iodine with autoimmune thyroiditis. Environ Health Perspect 1999, 107:749-752.
177. Doerge DR, Sheehan DM Goitrogenic and estrogenic activity of soy isoflavones. Environ Health Perspect 2002, 110:349-353.
178. Bergh JJ, Lin H-Y, Lansing L, Mohamed SN, Davis FB, Mousa S, et al. Integrin αVβ3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005, 146:2864-2871.
179. Maletzky BM, Shore JH Lithium treatment for psychiatric disorders. West J Med 1978, 128:488-498.
180. Bocchetta A, Loviselli A Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health 2006, 2:23.
181. Chakrabarti S Thyroid functions and bipolar affective disorder. J Thyroid Res 2011, 2011:1-13.
182. Lazarus JH The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998, 8:909-913.
183. Sundberg SA High-throughput and ultra-high-throughput screening: solution- and cell-based approaches. Curr Opin Biotechnol 2000, 11:47-53.
184. van der Ven L. Lower Organisms as Alternatives for Toxicity Testing in Rodents; with a Focus on Caenorhabditis elegans and the Zebrafish (Danio rerio), RIVM Report 340720003, National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands 2009.
185. Pekary AE, Levin SR, Johnson DG, Berg L, Hershman JM Tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta 1 (TGF-beta 1) inhibit the expression and activity of Na+/K(+)-ATPase in FRTL-5 rat thyroid cells. J Interferon Cytokine Res 1997, 17:185-195.
186. Ralduúa D, Babin PJ Simple, rapid zebrafish larva bioassay for assessing the potential of chemical pollutants and drugs to disrupt thyroid gland function. Environ Sci Technol 2009, 43:6844-6850.
187. Zatelli MC, Gentilin E, Daffara F, Tagliati F, Reimondo G, Carandina G, et al. Therapeutic concentrations of mitotane (o,p-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. Endocrinology 2010, 151:2453-2461.
188. Kuiper GGJM, Klootwijk W, Visser TJ Expression of recombinant membrane-bound type I iodothyronine deiodinase in yeast. J Mol Endocrinol 2005, 34:865-878.
189. Ekuase EJ, Liu Y, Lehmler H-J, Robertson LW, Duffel MW Structure-activity relationships for hydroxylated polychlorinated biphenyls as inhibitors of the sulfation of dehydroepiandrosterone catalyzed by human hydroxysteroid sulfotransferase SULT2A1. Chem Res Toxicol 2011, 24:1720-1728.
190. Martin LA, Wilson DT, Reuhl KR, Gallo MA, Klaassen CD Polychlorinated biphenyl congeners that increase the glucuronidation and biliary excretion of thyroxine are distinct from the congeners that enhance the serum disappearance of thyroxine. Drug Metab Dispos 2012, 40:588-595.